PMEF
OKUR

Point72 Middle East FZE’s OnKure Therapeutics OKUR Stock Holding History

Point72 Middle East FZE’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,395
Closed -$22.3K – 1394
2023
Q4 		$22.3K Buy
+1,395
New +$86.9K ﹤0.01% 1355

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Point72 Middle East FZE's OKUR Position: Q1 2024 in Review

Point72 Middle East FZE sold out of OnKure Therapeutics (OKUR) in Q1 2024, closing a stake of 1,395 shares — an estimated $22.3K sold.

Point72 Middle East FZE first reported a position in OKUR in Q4 2023 and held it in 1 quarter. The position peaked at $22.3K in Q4 2023. 61 funds tracked by Wall St. Rank hold OKUR as of Q1 2024.

  • Point72 Middle East FZE reported no remaining OnKure Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,395 OnKure Therapeutics shares in Q1 2024, an estimated $22.3K.
  • Point72 Middle East FZE first reported a position in OnKure Therapeutics in Q4 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's OnKure Therapeutics position peaked at $22.3K in Q4 2023.
  • 61 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.